← back to search

Jian Wu

Sun Yat-sen University · CN
Area of research
Surgery · Cancer Research
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Organ Transplantation Techniques and Outcomes, MicroRNA in disease regulation, and Cancer-related molecular mechanisms research.
h-index
54
citations
11,884
works
276
NIH funding
primary concept
Medicine
email

Recent publications

A Universal Strategy of Anti-Tumor mRNA Vaccine by Harnessing "Off-the-Shelf" Immunity.
2025cited by 8position: contributordoi
Thiostrepton suppresses intrahepatic cholangiocarcinoma progression via FOXM1-mediated tumor-associated macrophages reprogramming.
2025cited by 4position: contributordoi
GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses.
2025cited by 1position: contributordoi
Diverse RNA methylation patterns in neutrophils: key drivers in hepatocellular carcinoma.
2025cited by 1position: contributordoi
Systemic chemotherapy improves outcome of hepatocellular carcinoma patients treated with transarterial chemoembolization.
2025cited by 0position: contributordoi
Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study.
2025cited by 0position: contributordoi
A rare case of thymic carcinoma metastasize to liver.
2025cited by 0position: contributordoi
IRGM is a novel regulator of PD-L1 via promoting S6K1-mediated phosphorylation of YBX1 in hepatocellular carcinoma.
2024cited by 28position: contributordoi
Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study.
2024cited by 18position: contributordoi
Co-Delivery of siNRF2 and Sorafenib by a "Click" Dual Functioned Hyperbranched Nanocarrier for Synergistically Inducing Ferroptosis in Hepatocellular Carcinoma.
2024cited by 16position: contributordoi
Deep learning nomogram for preoperative distinction between Xanthogranulomatous cholecystitis and gallbladder carcinoma: A novel approach for surgical decision.
2024cited by 9position: contributordoi
Systematic pan-cancer analyses of the potential function of the Golgi scaffold protein PAQR3.
2024cited by 4position: contributordoi
Risk factors for post-operative portal vein stenosis in pediatric liver transplantation: a single center case-control study.
2024cited by 3position: contributordoi
Laparoscopic enucleation for pancreatic lipomatous hamartoma.
2024cited by 2position: contributordoi
Chinese guidelines for minimally invasive donor hepatectomy in living donor liver transplantation (2024 edition).
2024cited by 1position: contributordoi
Achieving laparoscopic anatomic resection for hepatocellular carcinoma by fluorescence guided positive staining of hepatic cone unit.
2024cited by 0position: contributordoi
Amino acid metabolism in health and disease
Signal Transduction and Targeted Therapy 2023cited by 471position: lastdoi
Amino acid metabolism in health and disease.
2023cited by 291position: contributordoi
Quality of Information in Gallstone Disease Videos on TikTok: Cross-sectional Study.
2023cited by 126position: contributordoi
Mitochondrial TSPO Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition and Immune Evasion.
2023cited by 89position: contributordoi
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial
Frontiers in Immunology 2023cited by 47position: middledoi
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial.
2023cited by 42position: contributordoi
N<sup>6</sup> -methyladenosine-modified circSTX6 promotes hepatocellular carcinoma progression by regulating the HNRNPD/ATF3 axis and encoding a 144 amino acid polypeptide.
2023cited by 38position: contributordoi
First evidence of neonicotinoid insecticides in human bile and associated hepatotoxicity risk.
2023cited by 30position: contributordoi
m<sup>6</sup>A-modification regulated circ-CCT3 acts as the sponge of miR-378a-3p to promote hepatocellular carcinoma progression.
2023cited by 24position: contributordoi
Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
2023cited by 22position: contributordoi
MVI-TR: A Transformer-Based Deep Learning Model with Contrast-Enhanced CT for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma.
2023cited by 20position: contributordoi
Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial.
2023cited by 18position: contributordoi
USP35 promotes HCC development by stabilizing ABHD17C and activating the PI3K/AKT signaling pathway.
2023cited by 14position: contributordoi
ST6GALNAC4 promotes hepatocellular carcinogenesis by inducing abnormal glycosylation.
2023cited by 12position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 12 papers (2020–2025)Shusen Zheng · Shandong University of Science and Technology11 papers (2013–2023) · 10 papers (2019–2023)Xiang Li · Army Medical University4 papers (2022–2024)Guoliang Shao · Wenzhou Medical University4 papers (2020–2023)Xueli Bai · Zhejiang International Studies University3 papers (2023–2025)Jianping Xiong · Jiangxi Normal University3 papers (2020–2021)Yuxian Bai · Harbin Medical University3 papers (2021–2023)Meili Sun · Shandong University3 papers (2021–2023)Li Bai · Academy of Medical Sciences3 papers (2021–2023) · 3 papers (2023–2025)Zhenggang Ren · Ministry of Education of the People's Republic of China2 papers (2020–2021)Li Xu · Jiangxi University of Traditional Chinese Medicine2 papers (2021–2021) · 2 papers (2020–2021)Shanzhi Gu · Harbin Medical University2 papers (2020–2021)Baiyong Li · China National Pharmaceutical Group Corporation (China)2 papers (2021–2023) · 2 papers (2020–2021)Lijie Song · BGI Group (China)2 papers (2021–2023)Jie Shen · Xinjiang Medical University2 papers (2020–2021)Jingfeng Liu · Beijing University of Chinese Medicine2 papers (2020–2021)